Advanced Radiotherapy Techniques to Reduce Mortality and Morbidity in Cervical Cancer

Cervical cancer is the 4th major killer of the women worldwide. Despite primary and advanced medical care and awareness levels in most part of the developed worlds, the mortality remained very high till date.

If it is localized at the time of diagnosis, the five year survival rate would by 61% in UK and if it is in the metastatic, it guarantees only 44% survival rate. Chemotherapy, followed by the radio therapy is the usual treatment procedure for the cervical cancer. Yet it could not reduce the mortality and morbidity and it is leading to hematologic toxicity, the radiation is also affecting the health cells in the body.

Intensity Modulated Radiotherapy (IMRT) and image guided brachytherapy (IGBT) are the recent advancements, capable of strictly confining to the target area. Exciting therapeutic and pharmacological methods are ensuring the improved survival rates due to effective treatment procedures.

PDF LINK

Molecular Targets in Lung Cancer Therapy: A Current Review

Cancer incidence worldwide has been increasing over the years. Lung cancer (LC) is a disease with a poor prognosis once diagnosed. LC is the leading cause of death in men worldwide and the second cause of mortality in women . In Portugal, LC remains as the leading cause of deathdue cancer in men. 

LC origins from oncogenic alterations in tissues from the respiratory epithelium, namely in bronchi, bronchioles and alveoli. This cancer results from multiple morphological, molecular and genetic changes, leading to an accumulation of malignant cells. LC is mainly classified into two categories, according to its histological characteristics: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is categorized into three different categories, namely adenocarcinoma, squamous cell carcinoma and large cell carcinoma.  Read More>>>>>>

Exceptional Therapeutic Outcome of Metastatic Neuroendocrine Tumor with Peptide Receptor Radionuclide Therapy with Brief Review of Literature

NETs are rare, heterogeneous group of neoplasm presented as chronic oncologic disease. Somatostatin analogue is the standard first line systemic therapy for mainly hormone control.

No standard second line systemic treatment is available except everolimus which has no reported complete response.

PRRT is an innovative molecular targeted treatment based on theragnostic concept for well differentiated NETs. We presented here a 63-year-old lady with grade 1 NET of rectum with lymphnodal and liver metastasis.

PDF LINK

Sentinel Lymph Node Mapping and Dissection in Patients with Endometrial Cancer

In developed countries, endometrial cancer (EC) is the most frequent cancer of the female reproductive system.

According to the recent recommendations and guidelines, systematic surgical staging represents the primary treatment of these patients.

However, the extent of this procedure should be carefully individualized according to the histological type and the patient’s general performance status.

PDF LINK

Personalized Medicine is the Key to Effective Cancer Treatment

Cancer is a disease involving abnormal cell growth with the potential to invade or metastasize to other parts of the body. The most common types of cancer in males are lung cancer, prostate cancer, colorectal cancer, and stomach cancer, and in females, the most common types are breast cancer, colorectal cancer, lung cancer, and cervical cancer.

In children, acute lymphoblastic leukemia and brain tumors are the most common types of cancer.

The risk of cancer increases significantly with age in addition to the many other risk factors such as the use of tobacco, obesity, lack of physical activity, environmental pollutants, viruses and many others.

PDF LINK

FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Connective tissue growth factor (CTGF) is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and facilitates local desmoplasia, tumor progression and metastasis in animal models.

This study evaluated safety and initial efficacy of the anti-CTGF antibody FG-3019 in combination with gemcitabine and erlotinib in patients with previously untreated Stage III or Stage IV PDAC.

Eight escalating FG-3019 doses/regimens ranging from 3 to 45 mg/kg Q2W and 17.5 and 22.5 mg/kg QW were evaluated. Toxicity, tumor response by CA19.9 and CT scan RECIST criteria, progression-free and overall survival were assessed.

PDF LINK

Childhood Cancer Care in Developing Countries; Challenge

Dealing with children who have cancer in developing countries is a great human experience not only for the patient and the family but also for persons who are caring them.

The diagnosis of a child as a cancer case is really a great shock to all family members and it is a moment of a dramatic change in their life. First reaction is usually a combination of sadness and denial.

They will start a new style of life with a plenty of investigations, appointments and different treatments decisions and plans. Different negative emotional reactions are the classic feelings of the parents every time they meet the treating physician.

PDF LINK